Equities Analysts Offer Predictions for ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Stock analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research note issued to investors on Sunday, November 9th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($0.86) for the year, down from their prior estimate of ($0.83). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals’ Q4 2025 earnings at ($0.31) EPS, FY2026 earnings at ($1.13) EPS, FY2027 earnings at ($1.05) EPS, FY2028 earnings at ($1.01) EPS and FY2029 earnings at ($1.10) EPS.

Several other equities analysts have also weighed in on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Eledon Pharmaceuticals in a report on Wednesday, October 8th. Zacks Research downgraded Eledon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Eledon Pharmaceuticals in a research note on Tuesday, September 2nd. Finally, Craig Hallum initiated coverage on shares of Eledon Pharmaceuticals in a report on Friday, July 25th. They set a “buy” rating and a $12.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Eledon Pharmaceuticals Stock Down 5.3%

Eledon Pharmaceuticals stock opened at $2.13 on Wednesday. The firm has a 50 day moving average price of $2.98 and a 200-day moving average price of $3.01. Eledon Pharmaceuticals has a twelve month low of $1.43 and a twelve month high of $5.08. The company has a market capitalization of $127.54 million, a P/E ratio of -1.82 and a beta of 0.63.

Eledon Pharmaceuticals (NASDAQ:ELDN) last announced its earnings results on Thursday, August 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.10.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ground Swell Capital LLC purchased a new stake in shares of Eledon Pharmaceuticals in the second quarter worth about $31,000. ProShare Advisors LLC bought a new stake in Eledon Pharmaceuticals during the 2nd quarter worth approximately $33,000. CW Advisors LLC bought a new stake in Eledon Pharmaceuticals during the 1st quarter worth approximately $34,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Eledon Pharmaceuticals in the 2nd quarter worth approximately $37,000. Finally, Y Intercept Hong Kong Ltd bought a new position in Eledon Pharmaceuticals in the 1st quarter valued at $41,000. 56.77% of the stock is currently owned by institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).